Pharmaceuticals, Biotechnology and Life Sciences
iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, has announced the presentation of new preclinical data for its lead program IMT-07 with product candidate OMX-0407, a first-in-class oral SIK3 inhibitor.
Thermo Fisher Scientific has announced new Norwegian-based sales and services team to support customers at every stage of an instrument’s lifecycle, during installation and for any potential maintenance needs, to minimize instrument downtime.
Kynos Therapeutics Ltd has emerged from stealth mode with £9 million to finance its lead KMO inhibitor (KMOi) programme through Phase 1 clinical trials and to progress its innovative pipeline of first-in-class KMOi across key indications in inflammation, immunity and metabolism.
The European Commission (EC) has expanded the marketing authorization for Sanofi’s Dupixent (dupilumab) in the European Union to include treatment of children aged 6 to 11 years as an add-on maintenance treatment for uncontrolled severe asthma.
Sandoz has announced the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
ViGeneron GmbH, a next-generation gene therapy company, has announced a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals Inc. (Regeneron) to develop and commercialize a gene therapy product based on ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD).
Nordic Nanovector ASA (OSE: NANOV) has announced that its Nomination Committee has nominated Dr Thomas Ramdahl for election as a Non-executive Director at the Company’s Annual General Meeting (AGM) on 28 April 2022.
Exscientia plc (Nasdaq: EXAI) has the appointed Michael Krams, M.D., as its Chief Quantitative Medicine Officer, to lead clinical development strategy for Exscientia’s portfolio of investigational medicines.
MGC Pharmaceuticals Ltd, a European based bio-pharma company specialising in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare , a part of UK health care group, Sciensus, for the distribution of CannEpil and CogniCann in key European territories and the UK
Novartis has announced new long-term data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension that demonstrated long-term efficacy and safety of Kesimpta (ofatumumab), with continued reduced risk of disability worsening, for people living with relapsing multiple sclerosis following up to four years of treatment.